Abstract
Background The present study analyzes the effects of each containment phase of the first COVID-19 wave on depression levels in a cohort of adults with a history of major depressive disorder (MDD).
Methods This analysis is part of the Remote Assessment of Disease and Relapse-MDD (RADAR-MDD) study. Individuals included had a diagnosis of DSM-5 major depressive disorder (MDD), at least two episodes of major depression (MDE), one of them in the previous two years. Depression was evaluated with the Patient Health Questionnaire-8 (PHQ-8) and anxiety with the Generalized Anxiety Disorder-7 (GAD-7). A total of 121 participants recruited from Catalonia were registered from November 1, 2019, to October 16, 2020. Levels of depression were explored across the phases (pre-lockdown, lockdown, four post-lockdown phases) of the restrictions imposed by the Spanish/Catalan governments. Then, a mixed model was fitted to estimate how depression varied over the phases.
Results A small but statistically significant rise in the depressive severity was found during the lockdown and phase 0 (early post-lockdown), as compared with the pre-lockdown phase in this sample with a history of MDD. Those with low pre-lockdown depression experienced an increase in depression levels during the “new normality”. We observed a significant decrease in the depression levels during the “new normality” in those with high pre-lockdown depression, compared to the pre-lockdown period.
Conclusion These findings suggest that COVID-19 restrictions impacted on the depression of individuals diagnosed with MDD, depending on their pre-lockdown depression severity. Furthermore, these subjects worsened when the restrictions were harder, during the lockdown and the early post-lockdown.
Competing Interest Statement
P. Annas is employed by the pharmaceutical company H. Lundbeck A/S. JM. Haro has received economic compensation for participating in advisory boards or giving educational lectures from Eli Lilly & Co, Sanofi, Lundbeck, and Otsuka. No other authors have competing interests to declare V.N. is an employee of Janssen Research and Development LLC. PA is employed by the pharmaceutical company H.
Funding Statement
The RADAR CNS project received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Unions Horizon 2020 research and innovation program and EFPIA (www.imi.europa.eu). This communication reflects the views of the RADAR-CNS consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein. The funding body was involved in the design of the study, the collection or analysis of data, and the interpretation of data.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
RADAR-MDD-Spain was conducted per the Declaration of Helsinki and Good Clinical Practice, adhering to principles outlined in the NHS Research Governance Framework for Health and Social Care (2nd edition). Ethical approval was obtained in Barcelona from the CEIC Fundacio Sant Joan de Deu (CI: PIC-128-17). All staff working on the study received training in study conduct, informed consent and risk assessment. RMT data was pseudonymised and stored in a research database in accordance with the General Data Protection Regulation. The informed consent process ensured that participants understood the nature of the study and the data being collected. Interested individuals were sent the study materials, including an information sheet and consent form, to review. If, after reading, they wished to participate, they were invited to an enrolment session which involved collecting written consent before administering any study procedures. They understood that their privacy was protected, that they could withdraw at any time without giving a reason, and requested to have all data collected from them deleted. Participants might not necessarily be in contact with healthcare services during the study. Still, for those that were, their relationships with their care teams were not impacted by participation or withdrawal from the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Abbreviations
- aRMT
- active remote measurement technology
- GAD-7
- item Generalized anxiety disorder-7 item
- IQR
- Interquartile ranges
- MDD
- Major depressive disorder
- ML
- maximum likelihood
- pRMT
- passive remote measurement technology
- PHQ-8
- Patient health questionnaire 8-item
- RADAR-CNS
- Remote assessment of disease and relapse - central nervous system
- REDCap
- Research electronic data capture
- RADAR-MDD
- Remote Assessment of Disease and Relapse-Major Depressive Disorder
